Balaxi Pharmaceuticals share price & results
- Jun 2026
- Jun 2026
Branded, IPR-driven pharma player selling generics and OTC essential medicines across frontier markets in Latin America and Africa via a produce-stock-sell distribution model, now backward-integrating with its own India manufacturing plant.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 80.7 | +14.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 5.8 | −0.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.3 | +348.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 1.01 | −11.1 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -17.35 | −4.7 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | -5.90 | −29.4 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −52.9% 1Y
1Y: ₹42.91 on 24 Oct 2025 → ₹20.21. High ₹43.08 (3 Nov 2025), low ₹15.67 (30 Mar 2026).
- Previous close
- ₹19.7
- Market cap
- ₹126 Cr
- 52-week range
- ₹15.67 – ₹43.08
- One year
- −51.96%
- Price to earnings (TTM to Jun 2026)
- 51.85×
- Return on equity (TTM to Jun 2026)
- 1.01%
Overview
- Symbol
- NSE:BALAXI
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Balaxi Pharmaceuticals Limited does
Based on the company's own presentations, annual report and earnings calls.
Balaxi Pharmaceuticals sources essential medicines - a mix of generics and branded generics - from WHO GMP-certified contract manufacturers in India, China and Portugal, then registers, brands and distributes them in frontier markets across Latin America (Guatemala, Dominican Republic, Honduras, El Salvador, Nicaragua) and Africa (Angola, Central African Republic) under a 'produce, stock and sell' model. Products reach patients through a network of 38 warehouses and an on-ground distribution fleet, backed by a portfolio of 964 product registrations across seven countries. The company is backward-integrating with its first own pharmaceutical formulation facility (General Oral Solid Dosage forms) at a Pharma SEZ in Jadcherla, Hyderabad, and is discontinuing an ancillary Building Hardware business to focus solely on pharmaceuticals.
Segments
- Africa distribution
- Latin America distribution
- Pharmaceutical manufacturing
- Building Hardware
- Product registrations
- 964 across 7 countries
- Countries of operation
- 7 (Guatemala, Dominican Republic, Angola, Honduras, El Salvador, Nicaragua, Central African Republic)
- Warehouses
- 38, with on-ground logistics fleet
- Manufacturing facility
- 1 (Pharma SEZ, Jadcherla, Hyderabad) - General Oral Solid Dosage formulations
- Overseas subsidiaries
- 7 wholly-owned (Dubai, Guatemala, Dominican Republic, Angola, El Salvador, Honduras, Nicaragua)
- Contract manufacturing sourcing
- WHO GMP-certified plants in India, China and Portugal
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +348% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 77 | 73 | 76 | 71 | 56 | 73 | 71 | 81 |
| Expenses | 67 | 69 | 64 | 67 | 55 | 69 | 71 | 76 |
| Operating profit | 11 | 4 | 13 | 4 | 1 | 3 | 0 | 5 |
| Operating margin | 13.7% | 5.4% | 16.4% | 5.9% | 2.1% | 4.3% | 0.2% | 5.8% |
| Other income | -4 | 4 | -2 | -2 | 2 | 0 | 3 | -1 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 6 | 6 | 10 | 1 | 1 | 2 | 1 | 2 |
| Tax rate | 17.4% | 11.7% | 10.6% | 67.0% | 84.1% | 80.8% | 56.4% | 38.3% |
| Net profit | 5 | 5 | 9 | 0 | 0 | 0 | 1 | 1 |
| EPS (₹ per share) | 0.83 | 0.97 | 1.57 | 0.05 | 0.04 | 0.06 | 0.11 | 0.24 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 336 | 241 | 293 | 270 |
| Expenses | 280 | 195 | 255 | 262 |
| Operating profit | 57 | 47 | 37 | 9 |
| Other income | 3 | -41 | -4 | 3 |
| Interest | 1 | 2 | 3 | 4 |
| Depreciation | 2 | 2 | 2 | 2 |
| Profit before tax | 57 | 2 | 29 | 5 |
| Net profit | 46 | -2 | 25 | 1 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 10 | 10 | 11 | 11 | 11 | 11 |
| Reserves | 103 | 173 | 190 | 221 | 227 | 238 |
| Borrowings | 4 | 13 | 19 | 53 | 57 | 58 |
| Other liabilities | 60 | 43 | 38 | 25 | 28 | 30 |
| Total liabilities | 176 | 240 | 258 | 310 | 322 | 337 |
| Fixed assets | 29 | 41 | 41 | 41 | 45 | 82 |
| Capital work in progress | 1 | 3 | 2 | 22 | 34 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 147 | 195 | 215 | 247 | 244 | 255 |
| Total assets | 176 | 240 | 258 | 310 | 322 | 337 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 0 | 34 | 6 | 5 | -35 | -4 |
| Cash from investing | -6 | -28 | -11 | -1 | -22 | -21 |
| Cash from financing | 4 | 0 | 26 | 30 | 34 | 0 |
| Net cash flow | -2 | 6 | 21 | 34 | -23 | -25 |
| Free cash flow | -3 | 7 | -9 | 4 | -57 | -25 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 121 | 36 | 57 | 84 | 138 | 184 |
| Inventory days | 29 | 184 | 189 | 233 | 173 | 202 |
| Days payable | 53 | 92 | 62 | 82 | 36 | 51 |
| Cash conversion cycle | 97 | 129 | 184 | 235 | 275 | 335 |
| Working capital days | 91 | 92 | 122 | 142 | 186 | 236 |
| Return on capital employed | 93.0% | 60.0% | 37.0% | 21.0% | 13.0% | 3.0% |
| Dividend payout | 0.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Promoters hold 65.99% as of Jun 2026; institutions added 0.00 pts since Mar 2026.
- Promoters 65.99%
- Foreign institutions 0.00%
- Domestic institutions 2.56%
- Public 31.45%
Who is on the register
Named in the Jun 2026 filing
Every holder of Balaxi Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 63.40% | unchanged | |
| AIF | 2.54% | unchanged |
| 1.86% | unchanged | |
| 1.64% | unchanged | |
| 1.41% | unchanged | |
| 1.41% | unchanged | |
| 1.29% | unchanged | |
| 0.96% | unchanged | |
| 0.70% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Balaxi Pharmaceuticals Limited
Free account: one company. Everything above stays public.
Write why you follow Balaxi Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Balaxi Pharmaceuticals Limited
Guides on how to read this kind of business and the numbers that matter.